Near East University Faculty of Medicine
Nicosia, 99138, Cyprus
NCT Number: NCT05066360
The production of AMH starts in granulosa cells before birth and the levels within the serum decreases towards the menapouse. The levels of AMH do not change throughout the menstruation cycle hovewer, it can be affected in cases related to body mass index (BMI), polycyctic ovarian syndrome (PCOS). The lower levels of AMH had been documented after ovarian surgery, radiotheraphy and chemotheraphy. AMH is a member of Transforming Growth Faktor β (TGF- β ) and it has receptors in brain structures including hyppocammpus. It is highly active neurophysiologically and it has a protective effect against N-methyl-D -aspartate related neuronal injury that is demonstrated both in vivo and in vitro studies. As a result, being a neuroactive hormone; AMH may have an effect on seizures within epileptic patients or serum AMH levels may be effected in epileptic patients when compared with healthy ones.
Looking for future studies?
Notify Me12 year–18 year
Female
Interventional
Not applicable
Nicosia, 99138, Cyprus
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
serum antimullerian hormone will be analyzed for all participants
Time frame: baseline, at the time of examination
The comparison of serum levels of anti-mullerian hormone between epileptic and healthy groups
Near East University, Turkey
Other
Investigation of Serum Antimullerian Hormone Levels in Adolescent Epilepsy Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06546410
Brain Diseases, Central Nervous System Diseases
Liverpool, United Kingdom
View Trial DetailsNCT07689084
Brain Diseases, Central Nervous System Diseases
Marburg, Hesse, Germany
View Trial DetailsNCT07689617
Brain Diseases, Central Nervous System Diseases
Elâzığ, Turkey (Türkiye)
View Trial DetailsNCT07667075
Brain Diseases, Central Nervous System Diseases
Haikou, Hainan, China
View Trial Details